D. Beal-Ardisson

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.

T. Petit, E. Blot, O. Trédan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.

A. Thiery-Vuillemin, A. Birtle, G. Ploussard, 2020, European urology.

Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study

A. Thiery-Vuillemin, A. Birtle, G. Ploussard, 2018, ESMO Open.

CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients

A. Arnaud, T. Bachelot, R. Largillier, 2023, Breast Cancer.

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

A. Fourrier-Réglat, F. Tubach, J. Prevost, 2019, British Journal of Cancer.

Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).

M. H. Poulsen, A. Birtle, G. Ploussard, 2018 .